Document resource
Objectives Systemic lupus erythematosus SLE is a chronic autoimmune disease affecting roughly 0.1% of the Portuguese population, characterized by relapsing flares and multi-organ involvement. Oral corticosteroids OCS remain central to therapy, yet long-term use and doses > 5 mg/day (prednisone equivalent) increase irreversible organ damage and diverge from current EULAR/ACR recommendations. This analysis provides the interim results of the TRANSfORM study, describing real-world OCS treatment patterns among adults with SLE managed in community pharmacies.Methods TRANSfORM is multicentric, cross-sectional observational study in community-pharmacies affiliated with the Association of Pharmacies ANF. Adults with self-reported, physician-diagnosed SLE were recruited by trained-pharmacists after informed consent signature, identified via hydroxychloroquine prescription, pharmacist-identified possible SLE, or patient self-referral. Inclusion required current or prior OCS using, or OCS prescription. Recruitment started June 2025, is ongoing and has 305 patients as target. Data were collected via e-CRF on sociodemographic, clinical, and pharmacological variables. Analyses used descriptive statistics.Results Preliminary findings use 203 enrolled patients data cut (mean age 56.3 ± 13.7 years; 87.2% female; 96.0% Caucasian). At enrolment, 88.2% were receiving hydroxychloroquine (n=179). Overweight/obesity prevalence was 60.1%, and 83.3% had > =1 comorbidity (primarily hypertension 43.8%, skin disorders 42.4%). Mean age at SLE diagnosis was 40.4 years. At recruitment, 52.7% (95% CI 45.8–59.6) were on OCS (50.2% starting, 0.5% ongoing, 2% uncertain with a current prescription), 39.9% were not on OCS, and 7.4% were unsure without a prescription. Among OCS users (n=107), 47.7% initiated OCS due to a flare and 95.3% reported previous OCS exposure. Among OCS users (n=107), prednisolone was most common (83.2%), followed by deflazacort (13.1%). Prescribing was predominantly by rheumatologists (57.9%) and internists (24.3%). Long term use (> =3 months) was frequent (87.9%); mostly fixed dose (58.9%). Among fixed-dose users (n=63), 32.8% received >5 mg/day (prednisone equivalent).Abstract PO:05:127 Figure 1Patient-reported awareness regarding the current status of oral corticosteroid (OCS) useConclusions Interim findings show substantial, prolonged OCS use in adults with SLE, many on fixed dose. Nearly 1/3 of fixed-dose users exceed the recommended maintenance >5 mg/day prednisone equivalent. Recruitment is ongoing; final results will be presented at SLEuro, providing an updated RWE overview of OCS use and underscoring the ongoing need for corticosteroids-paring strategies to optimize SLE care in Portugal.